Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
Corcept Therapeutics Announces Pricing of Private Placement Cash Sufficient to Fund Company Through Corlux NDA Submission
Corcept Therapeutics Announces Second Quarter 2009 Results and Development Highlights
Corcept Therapeutics Announces First Quarter 2009 Results and Development Highlights
Corcept Therapeutics Announces Fourth Quarter and Full Year 2008 Results and Update on Development Programs
Data Demonstrates Metabolic Benefits of Adding CORLUX(R) to Treatment With Risperdal(R)
CORLUX(R) Mitigates Weight Gain Associated With Risperdal(R), Expands on Proof of Concept Established in Earlier Trials
Trials Show Next-Generation GRII Receptor Antagonist Prevents and Reverses Weight Gain Associated With Use of Olanzapine -- the Active Ingredient in Zyprexa(R)
Caroline Loewy Joins Corcept as Chief Financial Officer
Corcept Therapeutics Announces Third Quarter 2008 Results
Corcept Therapeutics Continues Collaboration With Eli Lilly and Company
Corcept Therapeutics Announces Second Quarter 2008 Results
Corcept Therapeutics Announces First Quarter 2008 Results - Jun 1 2008 4:43PM
Corcept Therapeutics Announces Promising Results of Human Microdosing Study of Selective GR-II Antagonist - Jun 1 2008 4:43PM
Corcept Therapeutics Receives Nasdaq Delisting Notification
Corcept Therapeutics Announces $3 Million Private Equity Financing
Corcept Therapeutics Completes Enrollment in Third Phase 3 Study for Treating Psychotic Major Depression
Corcept Therapeutics Announces Third Quarter 2006 Results
Corcept Therapeutics Announces Negative Results From the Second of Three Phase 3 Studies Evaluating CORLUX(R) for Treating the Psychotic Features of Psychotic Major Depression
Corcept Therapeutics to Present at Merriman Curhan Ford 3rd Annual Investor Summit on September 18, 2006
Corcept Therapeutics to Present at Bear Stearns 19th Annual Healthcare Conference on September 12, 2006
Corcept Therapeutics to Present at Thomas Weisel Partners Healthcare Conference on September 7, 2006
Corcept Therapeutics Announces Second Quarter 2006 Results
Corcept Therapeutics Announces Publication of Phase 2 Clinical Study Results in the Journal of Biological Psychiatry
Corcept Therapeutics to Present at C.E. Unterberg, Towbin Emerging Growth Conference on July 11, 2006
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
